: Halo Therapeutics stock drops following weak 2023 outlook


Halozyme Therapeutics Inc. HALO, +1.20% stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hours, following a 1.2% gain to close the regular session at $55.70. The company forecast annual adjusted earnings of $2.50 to $2.65 a share on revenue of $815 million to $845 million with royalties of $445 million to $455 million. Analysts surveyed by FactSet had forecast $2.55 a share on revenue of $892.5 million with royalties of $478.2 million.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: The holiday PC market stunk for everyone except Apple, report says
Next articleLike the current rally in stocks? Enjoy it before you have to fret later in 2023


Please enter your comment!
Please enter your name here